• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Which Are the Most Dangerous Antidepressants?

Which Are the Most Dangerous Antidepressants?

June 1, 2017
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Daniel Carlat, MD Editor-in-chief, The Carlat Psychiatry Report Dr. Carlat has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Nelson JC and Spyker DA, Am J Psychiatry 2017;174(5):438–450

Study type: Retrospective cohort

We often prescribe antidepressants to patients who are suicidal, and unfortunately, some people use these very medications to try to kill themselves. It’s been known for some time that tricyclic antidepressants are among the most toxic in overdose, so we embraced the SSRIs and later medications in part because they are considered to be safer. But how safe are they? A new study attempts to answer that question.

Methods
Researchers identified all 48 FDA-approved medications likely to be prescribed for depression, and then searched for these drugs in the National Poison Data System, which lists all reports of poisoning in the U.S. There were more than 950,000 poisoning reports involving these medicines from 2000 through 2014.

The hazard level of the drugs was measured in two ways: a morbidity index, which described the proportion of exposures that led to an injury serious enough to require hospitalization (like an ICU admission for cardiac monitoring after a tricyclic ingestion); and a mortality index, which is the proportion of exposures that led to death. The people involved in these events had a mean age of 35.8 years, and 62.8% were female.

Results
This study reports a cornucopia of interesting results, and there’s no way to cover them all in this synopsis. Here are some of the highlights that we found especially clinically relevant.

The two most dangerous drugs of all 48 studied were the tricyclic amitriptyline (morbidity index of 345/1,000 and mortality index of 3.8/1,000) and lithium (325/1,000 and 1.3/1,000).

Not surprisingly, tricyclics and MAOIs as classes had the highest morbidity and mortality rates.

Clomipramine was the safest of all tricyclics and was similarly safe in overdose as drugs like citalopram and mirtazapine.

The “second generation” ADs were generally much safer than tricyclics and MAOIs (these included SSRIs, SNRIs, and others such as bupropion and mirtazapine). Within this group of safer drugs, here were some outliers:

— Bupropion and venlafaxine were ranked #1 and #2 respectively in highest mortality rates among the second-generation ADs; bupropion had the highest morbidity rate.

— Among the SSRIs, citalopram was the most dangerous, and in one comparison, it was four times more likely to be fatal than sertraline and escitalopram.

Among atypical antipsychotics, olanzapine and quetiapine had the highest morbidity rates, with respiratory depression being a particularly common problem with these agents.

TCPR’s Take
Before making wholesale changes in your prescribing habits, you should step back and realize how uncommon these bad events actually are. For example, bupropion, the “most lethal” of the second-generation ADs, led to 47 deaths out of over 62,000 overdoses over 15 years. The chance that one of your patients will OD on bupropion is already very scant, and then, among those rare overdose victims, less than 1 person out of 1,000 will die.

Nonetheless, there are a lot of thought-provoking data points in this paper that might affect our practices. If you’re deciding between amitriptyline and duloxetine for fibromyalgia, go with the much safer duloxetine. Bupropion and venlafaxine are the most likely to be hazardous among the newer ADs—which is unfortunate, since bupropion is on the list of first-line ADs for many clinicians. Citalopram really is more dangerous than its racemic cousin escitalopram, meaning that the FDA warning about citalopram dosing is sounding more reasonable than before.

The bottom line is that you should add these data to the many other factors you consider in deciding which antidepressant to prescribe. And don’t forget the basics, such as limiting refills to a weekly supply in patients at high risk of overdosing.
General Psychiatry
KEYWORDS antidepressants psychopharmacology research_updates
    Carlat 150x150
    Daniel Carlat, MD

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)

    More from this author
    www.thecarlatreport.com
    Issue Date: June 1, 2017
    SUBSCRIBE NOW
    Table Of Contents
    Take the CME Post-Test for Personality Disorders, TCPR, June 2017
    Which Are the Most Dangerous Antidepressants?
    FDA Approves First Drug to Treat Tardive Dyskinesia
    Diagnosing and Treating Narcissism
    Diagnosing and Treating Borderline Personality Disorder
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.